Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case-control study.

Epidemiological studies suggest that low levels of vitamin D (25OHD) constitute a risk factor for more aggressive prostate cancer. We examined the relationship between pre-diagnostic serum levels of vitamin D, parathyroid hormone (PTH), and calcium and risk of prostate cancer according to tumor aggressiveness.

We performed a nested case-control study within the Malmö Diet and Cancer Study on 943 incident prostate cancer cases. Tumor aggressiveness was defined by Gleason score, TNM stage, and serum levels of total prostate-specific antigen. Odds ratios (OR) were calculated for different quartiles of serum levels of 25OHD, PTH, and calcium, and for interactions between them.

We found no significant association when comparing aggressive to non-aggressive disease regarding vitamin D, PTH, or calcium. There was a trend toward an increased risk in low-grade tumors, i. e. , Gleason score ≤6, and a significant association regarding Gleason score 7 tumors with OR 1. 70 (1. 09-2. 65) in the highest quartile of vitamin D. Stratifying the analysis yielded several significant findings demonstrating a nonspecific interaction between the metabolites. In men with PTH above median, the risk of aggressive prostate cancer was double in the highest vitamin D quartile, OR 2. 01 (1. 24-3. 25), and for non-aggressive cancer 1. 82 (1. 25-2. 66). There was an inverse effect on risk of prostate cancer in men with PTH above median and vitamin D ≤50 nmol/L, OR 0. 25 (0. 09-0. 71) and calcium ≤2. 37 mmol/L, OR 0. 53 (0. 34-0. 82) for aggressive cancer.

This study showed no significant association when comparing aggressive to non-aggressive disease. There was a possible relationship between vitamin D and low-risk tumors. There were both positive and negative interactions between PTH, calcium, and vitamin D and risk of prostate cancer. These results were similar for low-risk and aggressive cases.

Cancer causes & control : CCC. 2015 Oct 30 [Epub ahead of print]

Johan Brändstedt, Martin Almquist, David Ulmert, Jonas Manjer, Johan Malm

Department of Urology, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden. Department of Surgery, Skåne University Hospital Lund, Lund University, Malmö, Sweden. , Department of Urology, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden. , Department of Plastic Surgery, Skåne University Hospital Malmö, Lund University, Malmö, Sweden. , Department of Laboratory Medicine, Section for Clinical Chemistry, Skåne University Hospital, Malmö, Sweden.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe